RoB 2: a revised tool for assessing risk of bias in randomised trials
In 2025, before the Wegovy pill was approved, the Wegovy injection was approved for treating the liver disease metabolic-associated steatotic hepatitis (MASH)
A recent study that was published in the New England Journal of Medicine (and also funded by Novo Nordisk) evaluated about 10,000 participants who had type 2 diabetes and also atherosclerosis or chronic kidney disease, or both
Evidence-based analysis of GH fragment vs GLP-1
For patients considering GLP-1 weight loss, medical weight loss, semaglutide, or tirzepatide, the goal should not be only to lose weight
A replacement dose delivers less than the internet promises and more than the doubters allow: in the most careful trial we have, a year of it gave older men with clearly low levels modest but real gains in energy, mood, sexual function, and strength (Snyder, New England Journal of Medicine, 2016)